A retrospective, multicentre, national non-interventional study evaluating the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice (REALMS study)
Latest Information Update: 02 Jun 2021
Price :
$35 *
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms REALMS
- 01 Jun 2021 New trial record
- 01 May 2021 Results published in the Neurological Sciences